Fraunhofer Institute for Translational Medicine and Pharmacology ITMP

Researchers at Fraunhofer ITMP have identified a promising approach for children affected by KCNQ2-related epilepsy. A drug originally developed as an antipsychotic has shown the ability to activate KCNQ2 potassium channels and significantly reduce seizure-like activity. The findings, based on patient-derived brain cells and animal models, suggest the potential of repurposing this compound into much‑needed therapy, opening up new hope for affected families.

In an increasingly complex and data-driven world, the need for innovative solutions for process optimization is growing. The Hamburg Fraunhofer Institutes (Fraunhofer CML, IAP, IAPT and ITMP) are working together to address relevant industrial applications with quantum computing.

Fraunhofer ITMP uses quantum computing to accelerate fundamental phases of drug research. In a video and a white paper, we explain the basics and how we have used quantum algorithms to better predict the molecular properties of drug precursor molecules.

Today's groundbreaking ceremony for the new Fraunhofer ITMP building in Penzberg marks a significant step forward in immunology and pandemic research. In close collaboration with our partners Roche, LMU Klinikum Munich, and Ludwig Maximilian University (LMU), we are creating a state-of-the-art research center that will develop innovative therapies and diagnostic systems. The new building will be an important location for research in the fight against infectious diseases and will provide space for future-oriented projects that strengthen the health of people and society.